entertainment -WSS

entertainment

author：knowledge 2025-09-29 22:50:27 - browse：69791

Adam's take main illustration — Molly Ferguson/STAT

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study.

A looming test for neoantigen cancer vaccines

Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that is resistant to immunotherapies like PD-1/PD-L1 inhibitors.

The Gritstone vaccine is designed to train a patient’s own T cells to recognize and kill cancer cells by targeting mutated cancer proteins, called neoantigens, that are unique to a patient’s own tumor. It’s a relatively new approach for cancer vaccines — made possible by powerful and relatively inexpensive genomic sequencing of tumors – that is intended to overcome all the previous failures in the field. Gritstone’s effort is also similar to one being used by Moderna and Merck that has reported encouraging results in melanoma — and is now being investigated in a Phase 3 study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： 'Revelatory' study finds a smoking impact that remains after quitting

hotspot

WSS

Vaccine advisory panel ACIP left half staffed by HHS

Biogen Alzheimer’s drug launch off to slow start

For Medicare Advantage, Democrats want stronger protections around AI

Biden report: The neurospychology of memory and aging

Key House Republican on health care plans exit from Congress

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

entertainment

entertainment

A looming test for neoantigen cancer vaccines

focus

Apple is now the first public company to be valued at $3 trillion

KalVista pill reduced swelling 'attacks' caused by genetic disease

At least 13 dead in Texas as scorching temps continue

J&J reports mixed data on next

In age of alternative facts, a scholarly course on calling out crap

Decentralized clinical trials need collaboration to achieve wider use

Alkermes shareholders re

Achieving telehealth equity for people with hearing loss

After affirmative action ruling, medical educators look to 'holistic review'

Key House Republican on health care plans exit from Congress

entertainment

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Unmasking the 'centricity' illusion in clinical trials

Why we need mandatory labeling of GMO products

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Guardant Health colon cancer test endorsed by FDA advisory panel

Private equity deals in Medicare Advantage declines

entertainment

hotspot

focus

explore